Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SEATTLE, May 16, 2017 -- Nohla Therapeutics Inc. (Nohla), a leading innovator in the development of off-the-shelf universal donor cellular therapies, announced today that Katie Fanning, the company’s president and CEO, will present at the 2017 Life Science Innovation Northwest Conference being held on May 23 and 24 at the Washington State Convention Center in Seattle. Ms. Fanning’s presentation will include an overview of the company’s technology platform, clinical progress, strategic vision, and near term milestones.
Ms. Fanning is scheduled to present on Tuesday, May 23, 2017 at 11:10 a.m. PDT at the Washington State Convention Center in room 618.
Ms. Fanning joined Nohla in February 2017 bringing over 30 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies. Having most recently served as Chief Operating Officer at VentiRx Pharmaceuticals, Ms. Fanning played an instrumental role in the strategic collaboration between VentiRx and Celgene Corporation.
Life Science Innovation Northwest is the largest annual life science conference in the Pacific Northwest. With more than 500 attendees, the conference offers networking and professional development for researchers and leaders at all stages. This year’s conference will include panel discussions on antimicrobial resistance, precision medicine, data collaboration, philanthrocapitalism, early-stage company investing, digital health, and federal policy. For more information, please visit http://www.lifesciencewa.org/?page=LSINW_17.
About Nohla
Nohla is a clinical stage company dedicated to the development of universal donor cellular therapies for the treatment of patients with blood cancers and other life threatening conditions. The Company is leveraging a platform developed over two decades of preclinical and clinical research, which enables the ex vivo expansion and directed differentiation of stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching).
Nohla is evaluating the ability of the first of these “off-the-shelf” products to reduce infection and other complications of neutropenia in two lead programs involving multi-center, randomized clinical trials: a Phase 2b study in the setting of cord blood transplant and a global Phase 2 study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML).
For more information, please contact: Jim DeNike Senior Director, Corporate Development & Investor Relations 206.519.5294 [email protected]
